Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients, \>=18 years of age;
HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting;
candidates for chemotherapy.
You may not be if
previous chemotherapy for metastatic or locally recurrent breast cancer;
concomitant hormonal therapy for metastatic or locally recurrent disease;
concomitant Herceptin therapy for treatment of metastatic or locally recurrent HER-2 positive disease;
previous radiotherapy for treatment of metastatic disease;
evidence of CNS metastases.
Clareo Health | A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
